Poster List
P001
Other
Unrestrained long-chain fatty acid catabolism kills Mycobacterium tuberculosis.
Tiago Beites, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto
P002
TB treatment
Insights into the use of cytochrome Bc inhibitors for future therapeutic strategies for tuberculosis
Clara Aguilar Perez, Johnson & Johnson Innovative Medicines
P003
Other
X-ray-based 3D histology of the human tongue and its coating using contrast-enhanced microCT imaging
Melanie Grobbelaar, Faculty of Medicine and Health Sciences, Stellenbosch University
P004
Non-tuberculous mycobacteria
M&Ms | The dependence of bacterial growth phase on Mycobacterium-Macrophage interaction
Tania Silva, i3S – Instituto de Investigação e Inovação e Saúde, Universidade do Porto
P005
Diagnostics
Enhancing tuberculosis diagnosis with a mathematical model integrating molecular test histories and patient-specific factors
Onya Opota, Institute of Microbiology, Lausanne University and University Hospital of Lausanne, Lausanne, Switzerland
P006
Drug susceptibility testing
Identification of Mycobacteroides abscessus complex subspecies and molecular determination of resistance to clarithromycin and amikacin
Fanourios Kontos, Laboratory of Clinical Microbiology, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
P007
Drug susceptibility testing
Subspecies distribution, and antibiotic susceptibility of Mycobacteroides abscessus complex isolates
Fanourios Kontos, Laboratory of Clinical Microbiology, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
P008
Drug susceptibility testing
Mycobacterial carbonic anhydrases as targets for tuberculosis research
Jenny Parkkinen, Tampere University
P009
Drug susceptibility testing
Applying whole genome sequencing to predict phenotypic drug resistance in Mycobacterium tuberculosis? Leveraging 20 years of nationwide data from Denmark.
Mads Lindholm Kurtzhals, Statens Serum Institut
P010
TB treatment
Pharmaco-toxicological profile of sulfonyl hydrazone derivatives with potent antimycobacterial activity
Violina Angelova - Stoyanova, Medical University of Sofia
P011
TB treatment
Defining genetic interdependencies essential for M. tuberculosis survival
Valwynne Faulkner, The Francis Crick Institute
P012
Omics and modelling
Strain Resolution Revolution: Phylogenetic Reconstruction and Rapid SNP Assay Development for Mycobacterium bovis in Ireland
Ryan Magee, Queen's University Belfast
P013
Non-tuberculous mycobacteria
Combined use of commercial and sequencing analysis methods for the identification of non-tuberculous mycobacteria in a tertiary Hospital of Athens: Seventeen years of experience
Fanourios Kontos, Laboratory of Clinical Microbiology, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
P015
Other
Simplified strategy to update tuberculosis transmission situation in Madrid by rationalizing molecular and genomic sequential analysis
Cristina Rodríguez-Grande, Instituto de Investigación Sanitaria Gregorio Marañón
P017
Omics and modelling
Overcoming H37Rv bias: a k-mer based approach to isolate-specific masking
Daniel Whiley, School of Science and Technology, Nottingham Trent University, Nottingham, UK
P018
Drug susceptibility testing
Genotypic and phenotypic drug susceptibility testing (DST) for Bedaquiline, Delamanid and Pretomanid in South-East Asian multi-drug resistant TB (MDR-TB) isolates
Tai Lee Kee, Singapore General Hospital
P019
Non-tuberculous mycobacteria
A M. abscessus tenosenovitis case: a diagnostic odyssey
Taeyang Chin, General Hospital Sint-Jan Brugge
P020
Non-tuberculous mycobacteria
NTM detection in a culture negative skin biopsy using bacterial sequencing: a case report
Taeyang Chin, General Hospital Sint-Jan Brugge
P021
Non-tuberculous mycobacteria
Genomic analysis of a Mycobacterium intracellulare subsp. chimaera variant cluster in a German hospital
Margo Diricks, Molecular and Experimental Mycobacteriology, Research Center Borstel, Leibniz Lung Center, Borstel, 23845, Germany
P022
TB treatment
The effect of diabetes mellitus on mortality during rifampicin-resistant tuberculosis treatment in Indonesia: a retrospective cohort study
Lara Veeken, Radboud University Medical Center
P023
Non-tuberculous mycobacteria
Characterization of a putative cobalt transport system in Mycobacterium smegmatis
Elke Goethe, University of Veterinary Medicine Hannover
P024
Omics and modelling
Illustrating variations in resistance mechanisms of Mycobacterium tuberculosis against bedaquiline
Teresa Walz, Research Center Borstel
P025
Non-tuberculous mycobacteria
In vitro activity of epetraborole, a novel LeuRS inhibitor, alone and in combination against rapidly growing non-tuberculous mycobacteria
Michael Cynamon, Veterans Health Research Institute, Syracuse, NY 13210, USA
P026
Omics and modelling
Tracking cross-border transmission of the Rwanda MDR-TB R3clone
Conor Meehan, Nottingham Trent University, Nottingham, UK
P027
Host pathogen and vaccines
Using the SpyTag/SpyCatcher system to determine the path of substrates through the mycobacterial type VII secretion system.
Yuwei Ding, Section Molecular Microbiology, Amsterdam Institute for Life and Environment (A-Life), Vrije Universiteit, Amsterdam, The Netherlands
P028
Drug susceptibility testing
Expanding resources for bedaquiline resistance detection: generating heteroresistant mixtures for BCCM/ITM inclusion
Anzaan Dippenaar, Institute of Tropical Medicine, Antwerp
P030
Omics and modelling
Detection a new Mycobacterium tuberculosis complex modern L2 taxon based on SNPs in the Rv2983 and fgd1 gene
Christophe Sola, Inserm, IAME, UMR1137, Université Paris Cité
P031
Omics and modelling
Genetic Diversity and Drug Resistance Profiles of Mycobacterium tuberculosis L2/Beijing Isolates in Kazakhstan: Insights from Whole-Genome Sequencing
Pavel Tarlykov, National Center for Biotechnology
P032
Non-tuberculous mycobacteria
Almost half of the newly described Mycobacterium species are published with synonymous genus names
Leen Rigouts, Institute of Tropical Medicine
P033
Drug susceptibility testing
Limited phenotypic resistance for African clinical Mycobacterium tuberculosis isolates harboring variants in genes relevant for bedaquiline and delamanid resistance.
F I Massou, University of Antwerp / Laboratoire de Référence de Mycobactéries
P034
Host pathogen and vaccines
Cerebrospinal fluid fatty acid metabolism and tuberculous meningitis mortality
Arjan van Laarhoven, Radboudumc Community for Infectious Diseases, Nijmegen, the Netherlands
P035
Omics and modelling
Predominant clones of Mycobacterium tuberculosis in Sub-Saharan African Countries
Faridath Massou, Laboratoire de Référence des Mycobactéries, Cotonou, Benin
P036
Omics and modelling
Endemic transmission of Mycobacterium tuberculosis sublineage Beijing L2.2.M3 within Colon, Panama: A prospective study
Fermin Acosta, Centro de Biología Celular y Molecular de Enfermedades, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología de Panamá, Ciudad del Saber, Panamá.
P037
Host pathogen and vaccines
Transcriptomic Insights into Human Macrophage Responses to Mycobacterium tuberculosis Complex (MTBC) Strains
Jana Schoenfeld, Molecular and Experimental Mycobacteriology, Research Center Borstel Leibniz Lung Center
P038
Non-tuberculous mycobacteria
Non-tuberculous and tuberculous mycobacteria prevalence and drug susceptibility in Italian and foreign subjects: a monocentric observational study
Sara Caldrer, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella (Verona), Italy
P039
Other
Genomic insights into TB transmission networks: unveiling diagnostic delays or subclinical cases and their impact on secondary cases
Laura Pérez, Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain
P040
One health
Healthcare Workers and Migrants User Experience with Targeted Education Materials for Self Swabbing for TB Screening
Renee Codsi, Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, WA, USA
P041
Non-tuberculous mycobacteria
Transmission patterns of Mycobacterium leprae in the Comoros
Sofie Braet, University of Antwerp
P042
TB treatment
Influence of external potassium on the rifampicin susceptibility of Mycobacterium
Vijay Srinivasan, Theoretical Microbial Ecology Group, Institute of Microbiology, Faculty of Biological Sciences, Friedrich Schiller University Jena, Jena, Germany
P043
Drug susceptibility testing
LiquidArray® technology for the detection of extended drug resistance mutations
Viktoria Szel, National Reference Laboratory for Mycobacteriology, Hungary
P044
Non-tuberculous mycobacteria
Mycothione reductase as a potential target in the fight against Mycobacterium abscessus infections
Linda De Vooght, University of Antwerp
P045
Host pathogen and vaccines
Impact of ageing on the immunotherapy effect of mycobacteria against cancer.
Esther Julian, Universitat Autònoma de Barcelona
P046
Omics and modelling
Machine learning approaches for the analysis of electrical signals from Oxford Nanopore Technologies to detect pharmaco-resistance in Mycobacterium tuberculosis
Alma Zinola, San Raffaele Scientific Institute
P047
TB treatment
Intrabacterial drug metabolism in Mycobacterium tuberculosis.
Valerie Maes, KU Leuven
P048
Omics and modelling
Are there blaC alleles out there that would naturally confer resistance to clavulanic acid?
Dylan Dissanayake, University of Oxford
P049
Other
The hidden diversity of Mycobacterium tuberculosis complex in Africa: the new L10 and the possible diversification histories of the complex
Guislaine Refrégier, Université Paris-Saclay
P050
Host pathogen and vaccines
Comparative study of two deleted Mycobacterium bovis strains in experimental animal models
Ximena Ferrara, Instituto de Agrobiotecnología y Biotecnología Molecular (IABIMO), UEDD INTA-CONICET; CICVyA, Instituto Nacional de Tecnología Agropecuaria
P052
TB treatment
Treating flies: Drosophila melanogaster for screening new therapies against tuberculosis
Maria Vidal Ramos, Unitat de Tuberculosi Experimental, Microbiology Dept. Germans Trias i Pujol Research Institute and Hospital (IGTP-HUGTIP), Badalona, 08916, Spain
P054
Drug susceptibility testing
Performance of open-access genomic drug resistance prediction tools for Mycobacterium tuberculosis: a systematic review and meta-analysis
Klaas Dewaele, KU Leuven
P055
One health
Two cases of Mycobacterium microti among primates in a zoo facility.
Dorte Bek Folkvardsen, International Reference Laboratory of Mycobacteriology, Statens Serum Institut
P056
Other
The effect of inhA promoter mutation on iron distribution in Mycobacterium tuberculosis
Marisa Klopper, Stellenbosch University
P057
Non-tuberculous mycobacteria
Oral administration of heat-killed Mycobacterium manresensis induces an increased response against subsequent infections in the Drosophila melanogaster model
Mariona Cortacans, Experimental Tuberculosis Unit (UTE), Institut de Recerca Germans Trias i Pujol (IGTP), Badalona (08916), Spain
P058
Drug susceptibility testing
Epidemiology, genetic diversity and drug susceptibility patterns by whole genome sequencing of Mycobacterium tuberculosis complex isolates in Gabon from 2012 to 2022
Viola Dreyer, Molecular and Experimental Mycobacteriology, Research Center Borstel - Leibniz Lung Center
P059
Other
Whole Genome Sequencing Analysis Reveals Interregional Transmission Dynamics of Tuberculosis in Spain: A Study of Catalonia and the Valencian Community
Iñaki Comas, Instituto de Biomedicina de Valencia, IBV-CSIC
P060
Other
Serratia sp. dominates the lung microbiome of patients with tuberculosis and non-tuberculous mycobacterial lung diseases
Meriem Belheouane, Research Center Borstel, Borstel
P061
Non-tuberculous mycobacteria
Diversity of nontuberculous mycobacteria in food animals: implications for food safety and one health
Gloria Ivy Mensah, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon/Accra, Ghana
P062
Drug susceptibility testing
A 3D-printed device for reproducible imaging of 96-well broth microdilution plates
Klaas Dewaele, Institute of Tropical Medicine Antwerp
P063
Drug susceptibility testing
Practical implementation of the WHO 2nd edition mutation catalogue in genotypic drug resistance detection pipelines
Jody Phelan, London School of Hygiene and Tropical Medicine
P064
Other
Population structure and transmission analysis of drug-resistant Mycobacterium tuberculosis´complex strains from Namibia based on whole genome sequencing.
Olga Shavuka, University of Namibia School of Medicine.
P065
Other
Integrating genomic surveillance for tuberculosis control in Catalonia
Pere-Joan Cardona, Microbiology Department, Laboratori Clínic Metropolitana Nord. Institut de Recerca i Hospital Germans Trias i Pujol (IGTP) – Badalona, Catalonia (Spain) / CIBER in Respiratory Diseases (CIBERES) – Madrid (Spain) / Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Catalonia (Spain)
P066
Host pathogen and vaccines
Establishing a 3D cell culture model of the tuberculosis granuloma as a drug-discovery platform.
David Pires, Center for Interdisciplinary Research in Health, Católica Medical School, Universidade Católica Portuguesa, Rio de Mouro, 2635-631, Portugal.
P067
Drug susceptibility testing
Drug resistance patterns in pulmonary tuberculosis patients in Namibia based on targeted Next Generation Sequencing.
Lusia Mhuulu, Department of Human, Biological & Translational Sciences, School of Medicine, University of Namibia, Namibia
P068
Omics and modelling
Exploring the adaptative landscape and factors impacting the epidemic success of Mycobacterium tuberculosis lineage 2 using simulations and genomic analyses
Nour Gharbi, EPHE, PSL University, Paris, France
P069
Omics and modelling
Nationwide temporal whole-genome sequencing analysis reveals high rates of clustering among multi-drug resistant Mycobacterium tuberculosis strains in South Africa
Christoph Wippel, Harvard Medical School
P070
TB treatment
Understanding pathways to chronic disease management for patients with tuberculosis in Haiti: A qualitative study
Joshua Ellis, Harvard Medical School
P071
Omics and modelling
TB Portals and the Quest for the Universal Reference Dataset.
Andrei Gabrielian, National Institute of Allergy and Infectious Diseases
P072
Drug susceptibility testing
Equivalent MIC results are observed by EUCAST BMD and MGIT for levofloxacin, moxifloxacin, D- cycloserine and linezolid
Manzour H Hazbón, BD
P073
Omics and modelling
UShER for Mycobacterium tuberculosis: an evaluation of pandemic-scale tools capacity to perform transmission surveillance
Francisco José Martínez Martínez, Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia, CSIC, Valencia, 46010 Spain
P074
Non-tuberculous mycobacteria
Detection of Mycobacterium avium subsp. paratuberculosis in fecal samples by culture in dairy farms in Panama
Fermin Acosta, Centro de Biología Celular y Molecular de Enfermedades, Instituto de Investigaciones Científicas y Servicios de Alta tecnología de Panamá (INDICASAT AIP), City of Knowledge, PANAMA
P075
Non-tuberculous mycobacteria
Genotyping of Mycobacterium leprae in humans and armadillos in a highly endemic area for leprosy in Brazil
Philip Noel Suffys, Laboratory of Molecular Biology Applied to Mycobacteria, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, Brazil
P076
Omics and modelling
From Research to Surveillance: Leveraging the State of Whole Genome Sequencing for Precision Public Health in a High-Burden Tuberculosis Setting
Emilyn Costa Conceicao, Instituto Evandro Chagas, Seção de Bacteriologia e Micologia, Ananindeua-PA, Brazil
P077
Omics and modelling
TOAST - A Tool for the design of targeted gene amplicons for the application of high throughput sequencing in genomic studies of tuberculosis
Linfeng Wang, London School of Hygiene and Tropical Medicine
P078
Host pathogen and vaccines
Analyzing the cell wall lipids of Bacillus Calmette Güerin (BCG) strains and pathogenic strains of the complex of Mycobacterium tuberculosis isolated from humans.
Gloria Guillermina Guerrero Manriquez, University Autonomous of Zacatecas
P079
Diagnostics
Can Emergence of Canonical Mechanisms of Isoniazid Resistance in Tuberculosis Be Predicted?
Siavash Valafar, Chicago Medical School
P080
Omics and modelling
Predictive AI Models for Personalized Prognosis of Tuberculosis Treatment
Siavash Valafar, Chicago Medical School
P081
Diagnostics
Xpert MTB/XDR assay: Rapid TB drug resistance detection
Sunil Kumar Dhatwalia, Post Graduate Institute of Medical Education Research , Chandigarh
P082
Drug susceptibility testing
Susceptibility patterns of Mycobacterium avium complex isolates recovered in two Greek University Hospitals
Fanourios Kontos, Laboratory of Clinical Microbiology, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
P083
Diagnostics
Broth microdilution plate-based minimal inhibitory concentration testing using MGIT-positive cultures
Praharshinie Rupasinghe, Institute of tropical medicine, Antwerp, Belgium
P084
TB treatment
Antimycobacterial activity of Bulgarian essential oils from Rosa species against reference and clinical Mycobacterium tuberculosis strains
Violeta Valcheva, Stephan Angeloff Institute of microbiology, Bulgarian Academy of Sciences
P085
Diagnostics
Reference-free clustering as an epidemiological tool for Mycobacterium tuberculosis strain typing
Aureliana Filomena Chambal Chilengue, Nottingham Trent University
P086
Diagnostics
Diagnostic accuracy of the LiquidArray MTB-XDR VER1.0 for the detection of Mycobacterium tuberculosis complex and fluoroquinolone, amikacin, ethambutol, and linezolid resistance
Margaretha de Vos, FIND, Geneva, Switzerland
P087
Non-tuberculous mycobacteria
NGS for the identification of less frequently encountered mycobacteria species in a clinical laboratory
Li-Hwei Sng, Singapore General Hospital
P088
Diagnostics
Pre-treat or Not pre-treat? Evaluation of DNA extraction pre-treatment procedures for Mycobacterium tuberculosis whole genome sequencing of clinical primary MGIT cultures
Emilyn Costa Conceicao, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
P089
Diagnostics
Whole genome sequencing analysis of M. tuberculosis from direct specimens: a hybrid capture approach
Godstime Stephen Kojo Morgan, San Raffael Scientific Institute
P090
Diagnostics
Whole genome sequencing analysis of M. tuberculosis from direct specimens: a hybrid capture approach
Godstime Stephen Kojo Morgan, San Raffael Scientific Institute
P091
TB treatment
The novel combination alpibectir/ethionamide (AlpE) is active on drug-sensitive and drug-resistant clinical isolates of Mycobacterium tuberculosis
Line Hofmann, Bioversys SAS
P093
Non-tuberculous mycobacteria
Evaluation of a new molecular diagnostic tool for the identification of NTM/MTB in positive MIGIT cultures
Sara Caldrer, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella (Verona), Italy
P094
Diagnostics
Excellent specificity and moderate to robust sensitivity of Xpert MTB/XDR for TB drug-susceptibility testing compared against Deeplex Myc-TB in nine African countries.
Faridath Massou, Laboratoire de Référence de Mycobactéries, Cotonou, Benin
P095
Diagnostics
Preliminary study on STANDARD™ M10 MTB/NTM, a RT-PCR multiplex test for management of TB and NTM patients.
Francesco Bisognin, Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
P096
Diagnostics
Growth Units in the MGIT below the instrument threshold to call resistance may be predictive of Rv0678 conferring resistance mutations
Elisa Ardizzoni, Institute of Tropical Medicine of Antwerp
P097
Diagnostics
Collision of three global pandemics: the effect of tuberculosis and HIV on the epidemiological, clinical, virological, and immunological trajectory of Covid-19 in household contacts
Mareli Claassens, University of Namibia
P098
Diagnostics
Collision of three global pandemics: the effect of tuberculosis and HIV on the epidemiological, clinical, virological, and immunological trajectory of COVID-19 in Botswana and Namibia at primary healthcare facilities
Mareli Claassens, University of Namibia
P099
Diagnostics
Better care through better quality control: Why quality control of DNA libraries is crucial for real-time sequencing of clinical cultures
Felicia Wells, DST NRF Centre of Excellence for Biomedical Tuberculosis Research
P100
Diagnostics
Rapid and sensitive detection of viable mycobacteria in bovine faeces and blood by a novel phagomagnetic separation (PhMS)-qPCR assay
Irene Grant, Queen's University Belfast
P101
Diagnostics
Novel duplex qPCR and LAMP assays suitable for differentiating Mycobacterium bovis from other Mycobacterium tuberculosis complex species in MGIT sputum cultures
Irene Grant, School of Biological Sciences, Queen's University Belfast
P102
Diagnostics
Evaluation of the cobas® MTB Real-Time PCR plus MTB-RIF/INH assay in a low incidence country
Janina Koglin, MVZ Labor Limbach Heidelberg
P103
Diagnostics
Resolution of phylogenetic typing in Mycobacterium tuberculosis: a comparison between WGS and tNGS
Anzaan Dippenaar, University of Antwerp
P104
Drug susceptibility testing
Low pH, high-throughput assay as a clinically relevant screening effort in Mycobacterium tuberculosis (H37Rv)
Peggy Janssens, Johnson &Johnson
P105
Non-tuberculous mycobacteria
The upstream region of Mycobacterium abscessus whiB7 as a culprit for poor treatment outcome?
Nathan De Boeck, KU Leuven - Centre of Microbial and Plant Genetics
P106
Non-tuberculous mycobacteria
Dialysis waters: should we look for Mycobacteria?
Angela Cannas, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy
P107
Diagnostics
Optimization of Mycobacterial tuberculosis complex sample processing for whole genome sequencing
Noud Hermans, KNCV Tuberculosis Foundation
P108
Drug susceptibility testing
Phenotyping resistance to bedaquiline and emerging medicines assessment by a fast RNA-based drug susceptibility test: TRACeR-TB
Amandine Sury, Scientific Service Bacterial Diseases - Infectious Diseases in Humans, Sciensano, Brussels, Belgium
P109
Diagnostics
The first evaluation of targeted nanopore-based sequencing for tuberculosis drug resistance detection
Kiarash Moghaddasi, San Raffaele Scientific Institute
P110
Drug susceptibility testing
Emergence of bedaquiline resistance in drug-resistant tuberculosis samples from Mozambique
Tatiana Fernando, National Institute of Health (INS) Mozambique
P111
Diagnostics
Evaluation of sample pre-treatment protocols for detection of mycobacterial DNA directly in sputum samples
Michaela Jonsson Nordvall, Department of Clinical Microbiology, University Hospital, Linköping, Sweden
P112
Non-tuberculous mycobacteria
Clinical characteristics and treatment of non-tuberculous mycobacterial skin and soft tissue infections: a retrospective case series
Wouter Peeters, Radboud University Medical Center
P113
Diagnostics
Validating the second edition of the WHO tuberculosis resistance catalogue using GPAS, a cloud platform for processing pathogen genetic data
Philip Fowler, University of Oxford
P114
Non-tuberculous mycobacteria
Non-tuberculous mycobacteria among previously treated tuberculosis patients with microscopy-positive and Xpert-negative results in Niger
Mahamadou Bassirou Souleymane Tiemogo, University of Antwerp, Department of Biomedical Sciences, Antwerp, Belgium
P115
Non-tuberculous mycobacteria
Non-tuberculous mycobacteria isolated at the end of the world
Ximena Ferrara, Instituto de Agrobiotecnología y Biotecnología Molecular (IABIMO), UEDD INTA-CONICET; CICVyA, Instituto Nacional de Tecnología Agropecuaria, Buenos Aires, Argentina
P116
Drug susceptibility testing
Deeplex® Myc-TB assay: Informing genotypic/phenotypic associations in Mycobacterium tuberculosis isolates
Melanie Grobbelaar, Faculty of Medicine and Health Sciences, Stellenbosch University
P117
Diagnostics
Investigating the resistance rate and transmission of Mycobacterium abscessus among cystic fibrosis and non-cystic fibrosis patients
Erik Michael Rasmussen, Biomedical Centre Martin, Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia
P118
Drug susceptibility testing
DprE1 inhibitors and bedaquiline combination for the treatment of TB: in vitro effect on MIC of susceptible and resistant M. tuberculosis strains
Andrea Muscetti, San Raffaele Scientific Institute
P119
Diagnostics
Tuberculosis screening among migrants: a qualitative study on healthcare seeking behaviour and acceptance of tongue swabs
Francesca Saluzzo, Universita Vita-Salute San Raffaele
P120
Non-tuberculous mycobacteria
Possible host genetic factors influencing leprosy susceptibility in a multiplex family from Anjouan, Comoros
Lena Kraußer, Institute of Tropical Medicine (ITM), Antwerp, Belgium
P121
Other
Comparison of DRB3.2 alleles among false-negative and positive tuberculin skin test cattle with bovine tuberculosis
Ximena Ferrara, Instituto de Agrobiotecnología y Biotecnología Molecular (IABIMO), UEDD INTA-CONICET; CICVyA, Instituto Nacional de Tecnología Agropecuaria
P122
Other
70 % ethanol preserves mycobacterial RNA from culture more efficiently than GTC-TCEP
Lena Kraußer, Institute of Tropical Medicine (ITM), Antwerp, Belgium
P123
Diagnostics
Demonstration of targeted next-generation sequencing using the Oxford Nanopore Technologies tuberculosis assay for the detection of drug resistant tuberculosis in Kyrgyzstan
Kristin Kremer, KNCV Tuberculosis Foundation, The Hague, The Netherlands
P124
Drug susceptibility testing
Establishing of drug susceptibility testing to Pretomanid
Elvira Richter, Labor Limbach
P125
Diagnostics
Experiences from a demonstration study on Nanopore sequencing for the diagnosis of drug-resistant tuberculosis in low-middle-income countries
Kristin Kremer, KNCV Tuberculosis Foundation, The Hague, The Netherlands
P126
Diagnostics
Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis
Maria Teresa Tórtola Fernández, Microbiology Service. Hospital University Vall d’Hebron
P127
Drug susceptibility testing
Using targeted Next Generation Sequencing directly from sputum for comprehensive drug resistance prediction of Mycobacterium tuberculosis strains in Namibia.
Lusia Mhuulu, Department of Human, Biological & Translational Sciences, School of Medicine, University of Namibia, Namibia
P128
Diagnostics
GPAS pipeline relatedness service for TB
Derrick William Crook, The University of Oxford
P129
Drug susceptibility testing
BTZ-043 exposure in vitro selects efflux pump mutants and BTZ-043, bedaquiline and clofazimine resistance in Mycobacterium tuberculosis
Arash Ghodousi, Vita-Salute San Raffaele University
P130
Drug susceptibility testing
Clusters of intrinsically delamanid/pretomanid cross-resistant strains of Mycobacterium tuberculosis in eastern Europe and central Asia.
Kurt Wollenberg, National Institute of Allergy and Infectious Diseases
P131
TB treatment
Cathelidicin, Vitamin D isoforms levels during the first month of anti-tuberculosis therapy.
Fermin Acosta, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología, Ciudad del Saber, Panamá
P132
Diagnostics
Acceptance of oral swabs for tuberculosis screening among healthcare workers: a qualitative study
Renee Codsi, Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, WA, 98195, USA
P133
Diagnostics
Routine investigations for tuberculosis on bronchoalveolar fluid lavage in a low-incidence setting: is it worth it?
Chiara Sepulcri, Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, 16132 Genova, Italy
P134
Diagnostics
LiquidArray MTB-XDR VER 1.0 - a powerful molecular genetic tool for rapid diagnosis of extensively drug-resistant tuberculosis
Vera Allerheiligen, Bruker-Hain
P135
Diagnostics
LiquidArray® Mycobacteria direct: Detection of MTBC and NTM directly from patient specimens
Vera Allerheiligen, Bruker-Hain
P136
Diagnostics
Analytical and Clinical performance evaluation of the FluoroType® MTBDR VER 2.0 with Dual Target Detection of Mycobacterium tuberculosis Complex from Native Sputum and Culture
Vera Allerheiligen, Bruker-Hain
P137
Non-tuberculous mycobacteria
Whole Genome Sequence of Mycolicibacterium parafortuitum Panama NTM 1 isolated from a cattle farm in Panama.
Fermin Acosta, Centro de Biología Molecular y Celular de Enfermedades, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT-AIP); Ciudad del Saber, Panamá.